Zentalis Pharmaceuticals, Inc.
ZNTL
$1.77
-$0.04-2.21%
| 09/30/2024 | 06/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -12.85% | 6.49% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -21.05% | -0.27% | |||
| Operating Income | 21.05% | -163.06% | |||
| Income Before Tax | 54.34% | -964.29% | |||
| Income Tax Expenses | -110.15% | 86.01% | |||
| Earnings from Continuing Operations | 54.51% | -979.25% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 54.51% | -976.81% | |||
| EBIT | 21.05% | -163.06% | |||
| EBITDA | 21.15% | -165.21% | |||
| EPS Basic | 54.55% | -975.07% | |||
| Normalized Basic EPS | 38.38% | -735.48% | |||
| EPS Diluted | 54.55% | -987.57% | |||
| Normalized Diluted EPS | 38.38% | -738.31% | |||
| Average Basic Shares Outstanding | 0.10% | 0.20% | |||
| Average Diluted Shares Outstanding | 0.10% | -0.21% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||
